Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi)
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
|
| Active substance |
|
| Therapeutic area (MeSH) |
|
| Procedure number |
EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014
|
| Regulatory outcome |
Variation
|
| DHPC type |
Referral - Article 20 procedure
|
| Referral name |
Janus kinase inhibitors (JAKi)
|
| Human ATC code |
|
| Dissemination date |
21/02/2023
|